Manager of formulary operations and strategy, Yale Health. Yale Health is a not-for-profit, physician-led health maintenance organization that provides integrated, patient-centered care to the university community.
I’m a Connecticut native with experience across multiple areas of pharmacy. I began as a pharmacy technician, steadily growing in responsibility while earning my Bachelor of Science degree from the University of Connecticut and my Pharm.D. from the University of Saint Joseph, followed by a PGY1 residency in home infusion with Option Care. My diverse experiences, along with my previous role as a residency preceptor, have deepened my understanding of the impact of managed care decisions on pharmacy operations and patient outcomes.
A key turning point in my career was when a mentor encouraged me to take on new roles and return to complete my Pharm.D. degree. The guidance from mentors and embracing a “next man up” mentality have shaped my career, reinforcing the importance of seizing opportunities and staying persistent in pursuing my goals.
In my current role, one of the biggest challenges is working in a smaller organization, where I often wear multiple hats. While demanding, I genuinely enjoy the dynamic nature of the work. It keeps me engaged across various aspects of pharmacy practice — from clinical care to operations — which helps me grow professionally and stay connected to the bigger picture.
My priority is to create a proactive framework for evaluating, covering and managing high-cost emerging therapies, ensuring timely access for patients while promoting financial sustainability.
I would improve access to quality, affordable healthcare by integrating providers across specialties, including mental health, and focusing on preventive care. Lowering costs and removing profit-driven barriers would ensure healthcare remains accessible to everyone.
I’ve been using nonproductive time, like driving, to learn through podcasts. I highly recommend “The Drive” by Dr. Peter Attia, especially the December 2024 episode on the U.S. healthcare system. Dr. Attia provides a data-driven perspective on key issues like healthcare access, cost and preventive care, covering a range of relevant topics for healthcare professionals to stay informed and think critically about the future of care.
As a new father, I’m embracing all the “firsts” with my daughter and enjoying watching her grow. This year, I aim to be more present and spend quality time with my family. Balancing professional responsibilities with family life is important to me, and I look forward to making lasting memories during this special time.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Report: Cyberattacks Have Impacted Patient Care, Nearly 20% of Healthcare Leaders Say
June 5th 2025Although 52% of healthcare leaders believe a fatal cyber-related patient incident will happen within the next five years, cybersecurity was not ranked as a top business challenge, according to the results of Omega Systems’ 2025 Healthcare IT Landscape Report.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Kathryn Boger, Ph.D. | 2025 MHE Emerging Leaders in Healthcare
June 5th 2025Co-founder and chief clinical officer, InStride Health. InStride Health provides evidence-based care for children, teens and young adults with anxiety and obsessive-compulsive disorder (OCD) and their families.
Read More
FDA Approved Bayer’s Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
June 5th 2025The approval is based on results from the phase 3 ARANOTE trial, which showed Nubeqa, when combined with androgen deprivation therapy (ADT), reduced the risk of radiographic progression or death by 46% compared to ADT with placebo.
Read More